Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: Pharmacodynamic effect

Clinical Therapeutics

Volumn 19, Issue 4, 1997, Pages 730-742

  Lowe, Franklin C ^a,b  

^a Columbia Univ Coll Phys Surgs ^*  (United States)

^b NONE   (United States)

Author keywords

Benign prostatic hyperplasia; Blood pressure effects; Drug interactions; Tambusolin

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; ENALAPRIL; NIFEDIPINE; PLACEBO; TAMSULOSIN;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; ELECTROCARDIOGRAM; EYELID EDEMA; HEADACHE; HOLTER MONITORING; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; MALE; MICROCAPSULE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PROSTATE HYPERTROPHY; PULSE RATE; VERTIGO;

EID: 0030801966     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80097-5     Document Type: Article

References (15)

1. Pool JL. Role of the sympathetic nervous system in hypertension and benign prostatic hyperplasia. Br J Clin Pract. 1994;74 (Suppl):13-17.
2. Boyle P. Epidemiology of benign prostatic hyperplasia: risk factors and concomitance with hypertension. Br J Clin Pract. 1994;74(Suppl):18-22.
3. 1-adrenoceptor antagonists in benign prostatic hyperplasia: Rationale and clinical experience. Eur Urol. 1996;29:129-144.
4. Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol. 1995;168(Suppl): 7-12.
5. 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol. 1996;29:145-154.
6. 1A-adrenoceptor antagonist. A metaanalysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol. 1996;29:155-167.
7. Data on file, Boehringer Ingelheim, Ridgefield, Conn., 1997.
8. 1 antagonist. In: Proceedings of the American Urological Association. Baltimore, Md: American Urological Association; 1996;155:585A. Abstract 1099.
9. Drizd T, Dannenberg A, Engel A. Blood pressure levels in persons 18-74 years of age in 1976-80, and trends in blood pressure from 1960 to 1980 in the United States. Vital Health Stat. 1986;234:1-68.
10. Starkey LP, Yasukawa K, Trenga C, et al. Study of possible pharmacodynamic interactions between tamsulosin and nifedipine in subjects with essential hypertension. J Clin Pharmacol. 1994;34:1019. Abstract 45.
11. Starkey LP, Trenga C, Miyazawa Y, Ito Y. Lack of clinical interaction effects between tamsulosin and enalapril. Clin Pharmacol Ther. 1995;57:166. Abstract PII-11.
12. Lowe FC. Safety assessments of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: A combined analysis. Urology. 1994;44:46-51.
13. Gillenwater JY, Conn RL, Chrysant SG, et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: A double-blind, placebo-controlled, dose-response multicenter study. J Urol. 1995; 154:110-115.
14. Fawzy A, Braun K, Lewis GP, et al. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: A multicenter study. J Urol. 1995;154: 105-109.
15. Wilde MI, Fitton A, Sorkin EM. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs Aging. 1993;3:258-277.